美屈孕酮

美屈孕酮
臨床資料
商品名（英语：Drug nomenclature）	Colprone, others
其他名稱	Metrogestone; Medrogesterone; AY-62022, NSC-123018, R-13615; 6,17α-Dimethyl-6-dehydroprogesterone; 6,17α-Dimethyl-4,6-pregnadiene-3,20-dione
懷孕分級	X;
给药途径	口服给药
藥物類別	孕激素
ATC碼	G03DB03 (WHO) ; G03FB07 (with estrogen);
法律規範狀態
法律規範	处方药（℞-only）;
藥物動力學數據
生物利用度	Nearly 100%
血漿蛋白結合率	95%: Albumin (90%), CBG (3%), SHBG (2%)
药物代谢	Hepatic (hydroxylation)
生物半衰期	35–36 hours
识别信息
	IUPAC命名法 (8R,9S,10R,13S,14S,17S)-17-acetyl-6,10,13,17-tetramethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one; ;
CAS号	977-79-7
PubChem CID	9949848;
DrugBank	DB09124;
ChemSpider	8125459;
UNII	077DN93G5B;
KEGG	D04885;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID70878637 ;
ECHA InfoCard	100.012.323
化学信息
化学式	C23H32O2
摩尔质量	340.51 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES O=C4\C=C3\C(=C/[C@@H]1[C@H](CC[C@@]2([C@@](C(=O)C)(CC[C@@H]12)C)C)[C@@]3(C)CC4)C;
	InChI InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1; Key:HCFSGRMEEXUOSS-JXEXPEPMSA-N;

美屈孕酮（英語：Medrogestone，研发代号：AY-62022，商品名：Colprone等）是一种有机化合物，化学式C
23H
32O
2，属于孕激素药物，用于婦科學的激素替代療法^[2]。

参考文献

^ ^1.0 ^1.1 Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins (PDF). Maturitas. December 2003, 46 (Suppl 1): S7–S16. PMID 14670641. doi:10.1016/j.maturitas.2003.09.014. ^{[永久失效連結]}
^ ^2.0 ^2.1 ^2.2 Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005, 8 (Suppl 1): 3–63. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875.
^ Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Reviews in Endocrine & Metabolic Disorders. 2002, 3 (3): 211–24. PMID 12215716. S2CID 27018468. doi:10.1023/A:1020072325818. Medrogestone The pharmacokinetics of medrogestone (5 mg dose) was studied in 12 Chinese young males who received a single oral dose of this drug [20]. The mean ± standard deviation Cmax was 8.21 ± 2.78 ng/ml and Tmax was 2.57 ± 1.02; the half-life of elimination was 34.9 ± 17.0 hours.
^ Lobo R, Crosignani P, Paoletti R, Bruschi F. Women's Health and Menopause: New Strategies — Improved Quality of Life. Springer Science & Business Media. 6 December 2012: 142–. ISBN 978-1-4615-1061-1.
^ Stanczyk FZ, Hapgood JP, Winer S, Mishell DR. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocrine Reviews. April 2013, 34 (2): 171–208. PMC 3610676 . PMID 23238854. doi:10.1210/er.2012-1008.

[SchindlerCampagnoli2003-1] 1.0 ^1.1 Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins (PDF). Maturitas. December 2003, 46 (Suppl 1): S7–S16. PMID 14670641. doi:10.1016/j.maturitas.2003.09.014. ^{[永久失效連結]}

[pmid16112947-2] 2.0 ^2.1 ^2.2 Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration (PDF). Climacteric. 2005, 8 (Suppl 1): 3–63. PMID 16112947. S2CID 24616324. doi:10.1080/13697130500148875.

[Stanczyk2002-3] Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Reviews in Endocrine & Metabolic Disorders. 2002, 3 (3): 211–24. PMID 12215716. S2CID 27018468. doi:10.1023/A:1020072325818. Medrogestone The pharmacokinetics of medrogestone (5 mg dose) was studied in 12 Chinese young males who received a single oral dose of this drug [20]. The mean ± standard deviation Cmax was 8.21 ± 2.78 ng/ml and Tmax was 2.57 ± 1.02; the half-life of elimination was 34.9 ± 17.0 hours.

[LoboCrosignani2012-4] Lobo R, Crosignani P, Paoletti R, Bruschi F. Women's Health and Menopause: New Strategies — Improved Quality of Life. Springer Science & Business Media. 6 December 2012: 142–. ISBN 978-1-4615-1061-1.

[StanczykHapgood2013-5] Stanczyk FZ, Hapgood JP, Winer S, Mishell DR. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocrine Reviews. April 2013, 34 (2): 171–208. PMC 3610676 . PMID 23238854. doi:10.1210/er.2012-1008.

[1]

[2]

[3]

[4]

[5]